282 related articles for article (PubMed ID: 33078472)
1. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
2. Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Person F; Meyer SC; Hopfer H; Menter T
Virchows Arch; 2021 Nov; 479(5):1013-1020. PubMed ID: 34164707
[TBL] [Abstract][Full Text] [Related]
3. [Myeloproliferative neoplasms related glomerulopathy].
Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasms cause glomerulopathy.
Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
6. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
7. Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report.
Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Iwasaki S; Ogawa Y; Hasebe N
Am J Kidney Dis; 2019 Dec; 74(6):844-848. PubMed ID: 31377025
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases.
Popov H; Koleva T; Stoyanov GS; Ghenev P
Cureus; 2022 Dec; 14(12):e32388. PubMed ID: 36632253
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
10. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.
Roupie AL; de Boysson H; Thietart S; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Decaux O; d'Aveni M; Rossignol J; Galland J; Solary E; Willems L; Schleinitz N; Ades L; Dellal A; Samson M; Aouba A; Fenaux P; Fain O; Mekinian A;
Autoimmun Rev; 2020 Feb; 19(2):102446. PubMed ID: 31838164
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Assi R; Kantarjian HM; Garcia-Manero G; Cortes JE; Pemmaraju N; Wang X; Nogueras-Gonzalez G; Jabbour E; Bose P; Kadia T; Dinardo CD; Patel K; Bueso-Ramos C; Zhou L; Pierce S; Gergis R; Tuttle C; Borthakur G; Estrov Z; Luthra R; Hidalgo-Lopez J; Verstovsek S; Daver N
Am J Hematol; 2018 Feb; 93(2):277-285. PubMed ID: 29134664
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
13. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
[TBL] [Abstract][Full Text] [Related]
14. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
15. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
Kuykendall AT; Tokumori FC; Komrokji RS
Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
[TBL] [Abstract][Full Text] [Related]
16. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
17. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
18. [The myeloproliferative neoplasms-related glomerulopathy].
Bardy A; Tiple A; Rabant M; Kémény JL; El Karoui K; Hermet M; Guettrot-Imbert G; Deteix P; Bay JO; Aumaître O; André M
Rev Med Interne; 2014 Apr; 35(4):222-30. PubMed ID: 23743480
[TBL] [Abstract][Full Text] [Related]
19. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
20. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
